UBS analyst Matthew Weston maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF248.00. The company’s shares closed yesterday at $250.79.
According to TipRanks, Weston is ranked #1555 out of 8735 analysts.
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $270.84, which is a 7.99% upside from current levels. In a report released today, Jefferies also maintained a Hold rating on the stock with a CHF240.00 price target.
RHHVF market cap is currently $204.1B and has a P/E ratio of 15.66.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- FDA approves Genentech’s Alecensa for adjuvant treatment
- Roche announces data from its Phase III OCARINA II study of OCREVUS
- Genentech reports data from OCARINA II study of Ocrevus
